


7.2.4 Compounds of Chapters 4.6 and 4.8

15,24,46,55-Tetrakis(hexyloxymethyl)-8,31,39,62,69,76-hexaaza-undecacyclo[58.2.2.1^{2,6}.2^{7,10}.1^{13,17}.1^{22,26}.2^{29,32}.1^{33,37}.2^{38,41}.1^{44,48}.1^{53,57}]hexaheptaconta-1(62),2,4,6(76),7,9,13,15,17(73),22,24,26(72),29,31,33,35,37(69),38,40,44,46,48(66),53,55,57(65),60,63,67,70,74-triacontaen-11,18,20,27,42,49,51,58-octayne 111

$C_{98}H_{90}N_6O_4$, $M = 1415.83$.



To a solution of $PdCl_2(PPh_3)_2$ (30 mg, 0.043 mmol) and CuI (8 mg, 0.043 mmol) in piperidine/THF (100 ml / 150 ml), a solution of **80a** (344 mg, 485 μ mol) in THF (25 ml) was added over a period of 4 days under stirring on air. It was stirred for two more days, the solvent evaporated, the soluble part of the

residue dissolved in CH_2Cl_2 , extracted with water (50 ml) and the aqueous phase again extracted with CH_2Cl_2 (50 ml). The combined organic phases were dried over $MgSO_4$, the solvent evaporated and the residue freeze-dried to give 1.00 g of a brownish solid material. By preparative GPC, cycle **111** (28 mg, 0.020 mmol, 8 %), oligomer [**111**]_{1.5} (26 mg, 0.012 mmol, 8 %), and oligomer [**111**]₂ (11 mg, 0.004 mmol, 3 %) were isolated as yellow, amorphous materials.

¹H-NMR (500 MHz, $CDCl_3$): $\delta = 8.44$ (s, 4 H, tpy-6,6''-H), 8.37 (s br, 4 H, tpy-3,3''-H), 8.14 (d, 4 H, $^3J = 7.0$ Hz, tpy-3',5'-H), 7.72 (s br, 4 H, tpy-4,4''-H), 7.66 (t, 2 H, $^3J = 7.5$ Hz, tpy-4'-H), 7.29 (s, 4 H, phenyl-H), 7.17 (s, 8 H, phenyl-H), 4.33 (s, 8 H, benzyl-H), 3.49 (t, 8 H, $^3J = 6.7$ Hz, α - CH_2), 1.67 (quintet, 8 H, hexyl- β - CH_2), 1.34-1.44 (m, 24 H, γ -, δ -, ϵ - CH_2), 0.94 (t, 3 H, $^3J = 6.8$ Hz, hexyl- CH_3).

MS (MALDI, THA): m/z (%) = 1513.81 [$M+CH_3+C_6H_{12}$]⁺, 1477.82 [$M+Na+K$]⁺, 1453.90 [$M+K$]⁺, 1437.89 [$M+Na$]⁺, 1429.90 [$M+CH_3$]⁺, 1415.90 [$M+H$]⁺, 1329.78 [$M-C_6H_{13}$]⁺.


Cyclic oligomer [111]_{1.5}

$C_{147}H_{135}N_9O_6$, $M = 2123.74$

MS (MALDI, THA): m/z (%) = 2145.34 [$M+Na$]⁺, 2137.28 [$M+CH_3$]⁺, 2123.32 [$M+H$]⁺.

*Cyclic oligomer [111]₂*C₁₉₆H₁₈₀N₁₂O₈, M = 2831.66

MS (MALDI, THA): m/z (%) = 2908.92 [M+Cu+CH₃]⁺, 2894.92 [M+Cu]⁺, 2846.82 [M+CH₃]⁺, 2832.42 [M+H]⁺, 2761.53 [M-C₅H₁₁]⁺, 2746.76 [M-C₆H₁₂]⁺, 2675.88 [M-C₅H₁₁-C₆H₁₂]⁺, 2660.95 [M-2C₆H₁₂]⁺. Only a spectrum in the linear mode (i.e., with less resolution than in the reflector mode) could be obtained. The different isotopes could therefore not be resolved.


*(5,5''-Diethynyl-2,2':6',2''-terpyridine-κ³N,N,N)copper(II) chloride 112*C₁₉H₁₁Cl₂CuN₃, M = 415.77

34 (50 mg, 0.12 mmol) was dissolved in degassed, dried methanol (15 ml) under reflux. Via a septum, a solution of CuCl₂•2H₂O (20 mg, 0.20 mmol) in methanol (7 ml) was added. The color of the greenish solution became darker.

After 5 min. of refluxing, the solution was allowed to cool to room temperature. A voluminous brownish precipitate was observed, which transformed during some minutes into green crystalline material. This was collected by filtration and washed with methanol, then ether to yield **112** (33 mg, 0.074 mmol, 67 %). As this Cu(II)-complex is paramagnetic, no NMR spectra were recorded.

MS (EI, 250 eV, 70°C): m/z (%) = 283 (2.8), 282 (20.3), 281 (100.0), 280 (9.3), 279 (1.4), 278 (1.2) [M-Cu-2Cl]⁺.

MS (FAB(+), DMSO-MNBA-Matrix): m/z (%) = 383 (16.7), 382 (21.0), 381 (80.3), 380 (29.0), 379 (100.0), 378 (4.5) [M-Cl]⁺, 347 (8.6), 346 (30.9), 345 (18.3), 344 (64.5), 343 (4.2) [M-2Cl]⁺.

*{5,5''-Bis[(3-bromo-5-hexoxyphenyl)ethynyl]-2,2':6',2''-terpyridine-κ³N,N,N}copper(II) chloride 113*C₄₃H₄₁Br₂CuCl₂N₃O₂, M = 926.07


The procedure was analogous to that described for **112**, with methanol replaced by acetone for reasons of solubility of **36** (**36**: 39 mg, 0.049 mmol;

$\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$: 8.4 mg, 0.049 mmol; acetone: 10 ml/5 ml). **113** (46 mg, 0.05 mmol, quant.) was isolated as green crystalline material.

MS (FAB(+), DMSO/MNBA-Matrix): m/z (%) = 895 (6.9), 894 (13.5), 893 (31.1), 892 (31.2), 891 (68.6), 890 (34.3), 889 (66.1), 888 (14.6), 887 (27.1) $[\text{M}-\text{Cl}]^+$, 858 (5.8), 857 (8.1), 856 (16.7), 855 (11.1), 854 (21.9), 853 (6.4), 852 (12.1) $[\text{M}-2\text{Cl}]^+$.

(5,5''-Bis[3-(3-[(triisopropylsilyl)ethynyl]-5-hexoxyphenyl)ethynyl]-5-hexoxyphenyl]-ethynyl)-2,2':6',2''-terpyridine- $\kappa^3\text{N,N,N}$)(2,2':6',2''-terpyridine- $\kappa^3\text{N,N,N}$)ruthenium(II) hexafluorophosphate **117**

$\text{C}_{108}\text{H}_{126}\text{F}_{12}\text{N}_6\text{O}_4\text{P}_2\text{RuSi}_2$, $M = 2019.40$



Under N_2 , **89b** (317 mg, 0.227 mmol) was heated in dioxane (20 ml) to 120°C . ethylene glycol (ca. 6 ml) was dropwise added until the two phases became a single phase. **114**¹⁷⁵ (100 mg, 0.227 mmol) was added, and the mixture

refluxed overnight. The brownish precipitate of **114** had then nearly vanished, and the solution was deeply red-brown. The mixture was poured into an aqueous NH_4PF_6 solution (50 ml) and stirred for 30 min. The dark-brown precipitate was filtered, thoroughly washed with water, and dissolved in dichloromethane. After repeated column chromatography over silica gel (first with $\text{CH}_3\text{CN}/\text{conc. KNO}_3(\text{aqu.})/\text{H}_2\text{O}$ 20:1:3, then 40:3:1), 100 mg (0.050 mmol, 22 %) of **117** was obtained as red-brownish solid. After another precipitation from NH_4PF_6 solution, 58 mg of **117** (0.030 mmol, 13 %) was isolated.¹⁸⁶

$^1\text{H-NMR}$ (500 MHz, CD_3CN): $\delta = 8.75$ (d, 2 H, $^3\text{J} = 8.5$ Hz, tpy-3',5'-H), 8.71 (d, 2 H, $^3\text{J} = 8.0$ Hz, tpy-3',5'-H), 8.48 (d, 2 H, $^3\text{J} = 8.5$ Hz, tpy-3,3''-H), 8.46 (d, 2 H, $^3\text{J} = 8.5$ Hz, tpy-3,3''-H), 8.42 (t, 1 H, $^3\text{J} = 8.0$ Hz, tpy-4'-H), 8.35 (t, 1 H, $^3\text{J} = 8.0$ Hz, tpy-4'-H), 7.96 (dd, 2 H, $^3\text{J} = 8.5$ Hz, $^4\text{J} = 1.5$ Hz, tpy(1)-4,4''-H), 7.90 (dt, 2 H, $^3\text{J} = 7.8$ Hz, $^4\text{J} = 1.0$ Hz, tpy(2)-4,4''-H), 7.41 (d, 2 H, $^4\text{J} = 2.0$ Hz, tpy(1)-6,6''-H), 7.34 (d, 2 H, $^3\text{J} = 5.0$ Hz, tpy(2)-6,6''-H), 7.17 (t, 2 H, $^3\text{J} = 6.0$ Hz, tpy(2)-5,5''-H), 7.16 (s, 2 H, phenyl-H), 7.11 (s, 2 H, phenyl-H), 7.06 (m, 2 H, phenyl-H), 7.01 (m, 2 H, phenyl-H), 6.99 (m, 2 H, phenyl-H), 6.94 (m, 2 H, phenyl-H), 3.95 (t, 4 H, $^3\text{J} = 6.5$ Hz, $\alpha\text{-CH}_2$), 3.90 (t, 4 H, $^3\text{J} = 6.5$ Hz, $\alpha\text{-CH}_2$), 1.66-1.74 (m, 8 H, $\beta\text{-CH}_2$), 1.36-1.44 (m, 8 H, $\gamma\text{-CH}_2$), 1.28-1.32 (m, 8 H, $\delta,\epsilon\text{-CH}_2$), 1.11 (s, 42 H, silyl-H),


0.86 (t, 12 H, $^3J = 7.5$ Hz, hexyl-CH₃). The assignment of the tpy-signals is not proven by 2-D spectra, but derives from comparison with literature data.¹⁷⁶

$^{13}\text{C-NMR}$ (125.8 MHz, CD₃CN): $\delta = 160.27, 159.10, 158.10, 156.44, 156.10, 155.15, 153.81, 141.06, 139.35, 137.38, 137.00, 128.64, 128.05, 127.66, 125.81, 125.69, 125.50, 125.37, 125.14, 125.05, 125.02, 124.62, 123.93, 119.92, 119.31$ (2 signals), 119.22, 107.03, 96.39, 92.49, 89.96, 89.27, 85.12, 69.58, 69.53, 32.32, 32.29, 29.86, 29.79, 26.38, 26.35, 23.37, 23.35, 19.10, 14.36, 12.21.

MS (MALDI, THA): m/z (%) = 1728.93 [M-2PF₆]⁺, 1874.94 [M-PF₆+H]⁺.

*{33-Hexoxy-15,22,44,51-tetrakis(hexoxymethyl)-8,58,72-triazaundecacyclo[54.2.2.1^{2,6}.2^{2,7}.1^{13,17}.1^{20,24}.2^{27,30}.1^{31,35}.2^{36,39}.1^{42,46}.1^{49,53}]diheptaconta-1(58),2,4,6(72),7,9,13,15,17(69),20,22,24(68),27,29,31,33,35(65),36,38,42,44,46(62),49,51,53(61),56,59,63,66,70-triacontaen-11,18,25,40,47,54-hexayne- $\kappa^3\text{N,N,N}$ }(2,2':6',2''-terpyridine- $\kappa^3\text{N,N,N}$)ruthenium(II) hexafluorophosphate **118***

C₁₁₈H₁₁₆F₁₂N₆O₅P₂Ru, M = 2089.25



The procedure was analogous to that described for **117**. **95a** (39 mg, 0.027 mmol), **114**¹⁷⁵ (12 mg, 0.027 mmol), dioxane (7 ml), ethylene glycol (ca. 2 ml). **118** (11 mg, 0.030 mmol, 13 %) was isolated as red-brown solid. The signals in the $^1\text{H-NMR}$ spectrum were too broad for assignment.

MS (MALDI, THA): m/z (%) = 2007.85 [M-PF₆-H+Cu]⁺, 1945.84 [M-PF₆+2H]⁺, 1861.82 [M-2PF₆-H+Cu]⁺, 1800.78 [M-2PF₆+2H]⁺.